GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ReNeuron Group PLC (OTCPK:RNUGF) » Definitions » Research & Development

ReNeuron Group (ReNeuron Group) Research & Development : $4.49 Mil (TTM As of Sep. 2023)


View and export this data going back to 2006. Start your Free Trial

What is ReNeuron Group Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. ReNeuron Group's Research & Development for the six months ended in Sep. 2023 was $2.69 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2023 was $4.49 Mil.

ReNeuron Group Research & Development Historical Data

The historical data trend for ReNeuron Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ReNeuron Group Research & Development Chart

ReNeuron Group Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.40 14.33 13.18 10.63 5.42

ReNeuron Group Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.96 4.91 3.38 1.79 2.69

ReNeuron Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $4.49 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ReNeuron Group  (OTCPK:RNUGF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

ReNeuron Group Research & Development Related Terms

Thank you for viewing the detailed overview of ReNeuron Group's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

ReNeuron Group (ReNeuron Group) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ReNeuron Group PLC (OTCPK:RNUGF) » Definitions » Research & Development
Comparable Companies
LSE:PYC LSE:NFX LSE:EVG LSE:APTA LSE:FAB LSE:IXI LSE:GENF LSE:OCTP LSE:VAL AQSE:INC OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX
Traded in Other Exchanges
RENE.GB:UK RENE:UK RQE1:Germany
Address
Pencoed Business Park, Pencoed, Bridgend, GBR, CF35 5HY
Website
https://www.reneuron.com
ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes the human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and U.S. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.